We partner with the media to inform the public of the global human crisis.
June 8, 2021Indivior Extends Leadership Position in Substance Use Disorder Treatment with Exclusive Agreement for Leading Asset Targeting Cannabis-Related Disorders....
April 30, 2021Indivior Applauds Biden Administration’s New Buprenorphine Practice Guidelines...
April 29, 2021Indivior Announces Q1 2021 Financial Results...
April 28, 2021Indivior Statement Regarding State Attorney General’s Recent Announcements Relating to SUBOXONE® (buprenorphine and naloxone) Film Settlements...
April 22, 2021Study Examining Impact of COVID-19 Pandemic on Opioid Use Disorder (OUD) Finds Greater Barriers to Care During Pandemic...
The information provided below is provisional and subject to change. Details of each event, including venue information, will be confirmed shortly before they are due to take place.
June 1, 2021
July 29, 2021
Global Media Contacts
EMEA, Australasia and China Financial Disclosure Reporting
Disclosure Of Payments, Donations & Joint Working
The Online Press Kit is designed to help media research our company for background information or follow-up stories. Please visit the links below to learn more.
About Indivior PLC – An overview of Indivior, including our worldwide locations and key products
Board of Directors – Biographies of Indivior’s Board
The Indivior PLC Pipeline – Information about the Indivior R&D efforts and progress of medicines in the pipeline